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Noncoding Y RNAs have recently been identified as essential factors for chromosomal DNA replication in human cell nuclei. Here,
we investigate the expression of human Y RNAs in tumours and test their requirement for cell proliferation. Relative expression
levels of all four human Y RNAs (hY1, hY3, hY4 and hY5 RNA) were determined by quantitative RT–PCR in extracts from human
solid tumours, corresponding nonmalignant normal tissues and derived cultured cells. On average, all four hY RNAs are significantly
overexpressed in solid tumours between 4- and 13-fold, compared to the corresponding normal tissues. In particular, hY1 and hY3
RNAs are overexpressed in carcinomas (and adenocarcinomas) of the bladder, cervix, colon, kidney, lung and prostate with
extremely high statistical significance (ANOVA, between groups, Po10e-22). A functional requirement of all four hY RNAs for cell
proliferation was investigated in a systematic survey for loss-of-function by RNA interference (RNAi). Degradation of hY1 and hY3
RNAs in human cell lines resulted in a significant cytostatic inhibition of cell proliferation. We conclude that noncoding hY RNAs have
potential both as new cancer biomarkers and as molecular targets for anti-proliferative intervention.
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Cancer is a disease characterised by uncontrolled cell proliferation
at the wrong time and place in a given tissue. Chromosomal DNA
replication is the major driving force for cell proliferation both
during normal development and in cancer. Proteins directly
involved in chromosome replication provide molecular biomar-
kers for cell proliferation and cancer. For instance, antibodies
specific for Cdc6 and MCM proteins allow the detection of
proliferating cells in tumours and normal tissues with high
specificity (Todorov et al, 1998; Williams et al, 1998; Freeman
et al, 1999). The most widely used proliferation biomarker in
clinical histopathology, however, is probably Ki-67. Antibodies
specific for Ki-67 protein have been established as useful
diagnostic biomarkers for identifying proliferating cells within a
given cell population (reviewed by Scholzen and Gerdes, 2000;
Brown and Gatter, 2002). The cellular function of Ki-67 protein is
still unclear, but depletion of Ki-67 protein by antisense
oligonucleotides directed against Ki-67 mRNA leads to an
inhibition of cell proliferation and tumour growth, suggesting
that Ki-67 protein is functionally involved in cell cycle progression
and may be a potential target in anticancer therapy (Kausch et al,
2003).
In addition to proteins, noncoding RNAs are also involved in the
regulation of most biological processes (reviewed by Michel, 2002;
Storz and Wassarman, 2004; Bernstein and Allis, 2005), therefore
making them highly relevant for cancer research. It has recently
been established that the expression patterns of noncoding
microRNAs (miRNAs) are altered in many human cancers
(reviewed by Garzon et al, 2006; Hammond, 2006; Osada and
Takahashi, 2007). Several miRNAs are overexpressed in cancers,
such as the miR-17-92 cluster in lymphomas and cancers of the
lung, prostate, colon and breast, suggesting that they may function
as oncogenes. Conversely, the expression of some miRNAs is
reduced in malignancies, such as let-7 in lung cancers, suggesting
that miRNAs can function as tumour suppressors. Consequently,
expression patterns of noncoding miRNAs may be used as
proliferation biomarkers, and they could even be used as potential
targets for therapeutic intervention. A pioneering study in mice
has established that silencing of miRNA levels is feasible in vivo by
injection of modified antisense oligonucleotides called ‘antago-
mirs’ (Krutzfeldt et al, 2005).
A different class of noncoding RNAs termed Y RNAs has been
shown to be functionally required for chromosomal DNA
replication in mammalian cell nuclei (Christov et al, 2006).
Y RNAs were originally identified as the RNA component of
soluble ribonucleoproteins, which are detected by sera from
patients suffering from systemic lupus erythematosis (Lerner et al,
1981). Four Y RNAs are present in human cells: hY1, hY3, hY4 and
hY5, ranging in size from 83 to 112 nucleotides (Hendrick et al,
1981), and they fold into characteristic stem-loop structures
(O’Brien et al, 1993; van Gelder et al, 1994). Each hY RNA is
encoded by a single functional gene, which is transcribed by RNA
polymerase III from an upstream type 3 promoter (Hendrick et al,
1981; Maraia et al, 1994, 1996; Matera et al, 1995). The Y RNA
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sgenes have been conserved during vertebrate evolution, even
though different numbers of active Y RNA genes exist in different
species due to gene losses, duplications and rearrangements
(Mosig et al, 2007; Perreault et al, 2007). Our recent observation
that hY RNAs are functionally required for semiconservative
mammalian chromosomal DNA replication (Christov et al, 2006)
warrants an investigation into whether Y RNAs may also play a
role in cell proliferation and cancer.
In this study, we analyse the expression of hY RNAs in human
tumours and corresponding nonmalignant tissues by quantitative
real-time PCR, and investigate their functional requirement for cell
proliferation in human cell lines by RNA interference. Our results
show that human Y RNAs are significantly overexpressed in
human solid tumours, and their degradation results in an
inhibition of cell proliferation.
MATERIALS AND METHODS
Cell culture
All cell lines were propagated as subconfluent monolayer cultures
in DMEM-medium, supplemented with 10% foetal bovine serum,
10Uml
 1 penicillin, 0.1mgml
 1 streptomycin and 2.5mgml
 1
amphotericin B (Fungizone) (all Gibco Invitrogen, Carlsbad, CA,
USA). Cell viability was assessed by exclusion of trypan blue
(Sigma-Aldrich, St Louis, MO, USA), as described (Nabatiyan et al,
2006).
RNA samples
Pools of tissue-specific RNA A panel of total RNA purified from
pools of 20 different human normal tissues (FirstChoice
s Human
Total RNA Survey Panel, NO AM6000) was purchased from
Ambion (Ambion-ABI, Austin, TX, USA). Each pool contains
purified total RNA from three tissue donors.
Individual samples from specific anatomic sites RNA samples
purified from specific anatomic sites of anonymous patients were
purchased from Clinomics BioSciences (Watervliet, NY, USA).
Each sample is derived from a defined anatomical site of healthy or
cancer origin (carcinoma and adenocarcinoma), obtained from
surgeries.
Soluble RNA from human cultured cells Total soluble RNA was
obtained from human cultured cells by hypotonic extraction and
purified by phenol extraction and ethanol precipitation, as
described (Christov et al, 2006).
Quantitative RT–PCR
cDNA was synthesised from commercially obtained pure RNA
samples using random sequence hexamer primers (Sigma-
Genosys, Haverhill, Suffolk, UK), or from RNA purified from
human cultured cells using a set of specific primers complemen-
tary to the 30 ends of all tested RNAs as described (Christov et al,
2006).
Relative RNA expression levels in extracts from human tissues
were determined by quantitative PCR on a PRISM 7900HT
sequence detection system (Applied Biosystems Incorporated,
ABI, Foster City, CA, USA), with the following settings: 10min at
961C, 15s at 961C and 1min at 601C for 50 cycles. The MKI67
TaqMan Assay (Assay ID Hs00606991_m1; ABI) was used for
amplification of Ki67 cDNA, and the HPRTI TaqMan Assay (Assay
ID 4326321E; ABI) was used for amplification of HPRT cDNA. The
TaqMan Universal PCR Master Mix (ABI) was used for these
amplification reactions. The SYBR Green PCR Master Mix (ABI)
was used for the hY RNA-derived cDNA templates, using the hY
RNA-specific primer pairs (200nM) described previously (Christov
et al, 2006).
Relative RNA expression levels in extracts from cultured human
cells were determined by quantitative PCR on the iCycler iQ
platform (Bio-Rad, Hercules, CA, USA), using the iQ SYBR
s Green
Supermix labelling kit (BioRad), using conditions and primer pairs
exactly as described previously (Christov et al, 2006). In addition,
Ki67 cDNA was amplified by the following primer pair: Ki67a:
CAGGTCAGGAAGGTCTACAG, Ki67b: TTGTTGTAGTAGTGTTG
CCT (Sigma-Genosys).
For each sample, the differences in threshold cycles between the
experimental RNAs and a calibrator RNA (HPRT mRNA) were
determined as follows: DCt¼Ctexperimental Ctcalibrator.
Mean values of at least three parallel sets of data acquisitions
were used per data point. Relative expression levels were
determined from the mean DCt values as follows: relative
expression level¼2 exp DCt.
Statistics
Spearman’s rank correlations and analysis of variance (ANOVA) of
DCt values were computed using the R software package (http://
www.r-project.org). T-tests were performed using Microsoft Excel.
RNA interference in vivo
Primer pair sequences used to direct generation of siRNAs in vitro
are detailed in the supplementary material. Individual siRNAs were
chemically synthesised using an Ambion Silencer
s siRNA
construction kit as detailed previously (Nabatiyan and Krude,
2004). Transfections were performed with 10nM siRNAs using
Lipofectaminet 2000 reagent (Invitrogen, Carlsbad, CA, USA) and
OptiMEM
s (Gibco Invitrogen), as specified by the supplier.
Identical concentrations of Lipofectamine were used for all
siRNAs.
RESULTS
Expression profiles of hY RNAs in human tissues
Expression levels for each of the four hY RNAs were determined by
quantitative RT–PCR and expression levels were normalised to
HPRT mRNA, which shows very low variation in expression levels
between different human tissues and cell types (Vandesompele
et al, 2002; de Kok et al, 2005). We initially determined the relative
expression levels of all four hY RNAs in a selection of 20
nonmalignant human tissues, and compared them to the levels of
the proliferation biomarker Ki-67 mRNA.
All four hY RNAs and Ki-67 mRNA were expressed in all tissues
investigated (Figure 1). The relative expression levels of the four
individual hY RNAs varied far less between different tissues than
Ki-67 mRNA (Figure 1). The three large hY RNAs hY1, hY3 and
hY4 showed significantly and positively correlated relative
expression levels across different tissue types (Spearman’s rank
correlation coefficients: hY1 vs hY3, Rs¼0.833, P¼2.2 10
 16;
hY1 vs hY4, Rs¼0.747, P¼2.3 10
 4; hY3 vs hY4, Rs¼0.839,
P¼2.2 10
 16). hY5 expression levels were positively but non-
significantly correlated to the other three hY RNAs (hY1 vs hY5,
Rs¼0.472, P¼0.037; hY3 vs hY5, Rs¼0.449, P¼0.048; hY4 vs
hY5, Rs¼0.220, P¼0.349). Finally, the hY RNA expression levels
were either not correlated or were positively but nonsignificantly
correlated with Ki67 mRNA expression levels (hY1 vs Ki67,
Rs¼ 0.003, P¼0.992; hY3 vs Ki67, Rs¼0.239, P¼0.307; hY4 vs
Ki67, Rs¼0.186, P¼0.428; hY5 vs Ki67, Rs¼0.320, P¼0.167).
The observation that some pairs are strongly correlated while
others are substantially weaker allows two basic conclusions. First,
expression levels of hY RNAs do vary with tissue type. Second,
while the expression of hY1, hY3 and hY4 RNAs are to some extent
Y RNAs as cancer biomarkers
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separate.
Elevated hY RNA expression in human tumours
To assess a role for hY RNAs in cancer, we determined the relative
RNA expression levels in human solid tumours (42 samples) and
corresponding healthy nonmalignant tissues (24 samples). These
samples contain representatives from six different tissue types:
urinary bladder, cervix, colon, kidney, lung and prostate. We first
investigated the overall distributions of relative expression levels of
Ki-67 mRNA and the four hY RNAs in all tumour and healthy
tissue samples (Figure 2), and secondly differentiated these results
according to the six different tissue types (Figure 3 and Table 1).
The overall range of relative Ki-67 mRNA expression overlaps
between normal and tumour samples (Figure 2A), but the mean
Ki-67 mRNA expression was 1.6-fold higher in the tumour samples
compared with normal tissue samples (Figure 2B). This slight
overall increase was not significant (t-test, two-tailed, unpaired,
32768
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Figure 2 Elevated relative expression of hY RNAs in human cancer
tissue compared to corresponding normal nonmalignant tissues. Expression
levels of the indicated RNAs were determined by qRT–PCR relative to
HPRT mRNA in extracts from 24 individual normal tissue samples and 42
individual carcinomas and adenocarcinomas. (A) Distributions of relative
RNA expression levels. Box and whisker plots are shown for the
distributions of relative expression levels for each RNA as indicated. Thin
vertical lines indicate range, boxes indicate the 25th–75th percentile and
black horizontal lines indicate the median for each distribution. Light grey
boxes represent normal sample distributions, dark grey boxes represent
tumour sample distributions. (B) Elevated hY RNA expression in tumours.
The relative expression of these RNAs in tumour samples compared to
corresponding normal tissue samples was calculated by dividing the mean
expression level of all tumour samples by the mean value of the normal
nonmalignant samples.
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Figure 1 Relative expression levels of hY RNAs in human tissues.
Expression levels of the indicated RNAs were determined by qRT–PCR
relative to HPRT mRNA in extracts from 20 different human tissues. Mean
values of three separate data acquisitions per tissue sample are shown. The
expression level of HPRT mRNA is set as one. Mean relative expression
values for each RNA across all tissues examined are indicated by a
horizontal light grey line, and s.d. from the mean (± std) by brackets to the
right of each panel.
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sP¼0.172). However, Ki-67 mRNA expression was strongly increased
in tumours of the bladder, cervix, kidney and lung, whereas it was
actually reduced in colon and prostate tumours (Figure 3).
The overall ranges of relative hY RNA expression show a partial
overlap, with a general upward shift in expression level from
normal to tumour samples (Figure 2A). Overall, the mean relative
expression levels of all four hY RNAs are increased in tumours
compared to normal tissue, ranging from 4-fold for hY4 to 13-fold
for hY1 (Figure 2B). This increase was significant for each of the
four hY RNAs (t-test, two-tailed, unpaired, Po0.005). Importantly,
all hY RNAs were overexpressed in tumours of all six-tissue types
investigated (Figure 3). However, we note three exceptions from
the overall trend: the highest levels of hY1, hY3 and hY4
overexpression were observed in kidney tumours, a very high
level of hY5 overexpression in lung tumours, and no or borderline
overexpression was observed for hY4 RNA in bladder, lung and
prostate tumours (Figure 3). Taken together, these data strongly
suggest that human carcinomas (and adenocarcinomas) have
elevated hY RNAs expression levels compared to the correspond-
ing healthy tissue.
To determine the statistical significance of these results, we
performed an analysis of variance (two-way ANOVA) on the original
qRT–PCR data (Table 1). For each RNA in turn, we fitted a model
with the explanatory factors malignancy type (tumour vs normal),
t i s s u et y p e( b l a d d e rvs cervix, colon, kidney, lung and prostate) and
the interaction between malignancy type and tissue type.
For Ki-67 mRNA, the most significant factor was interaction
between malignancy type and tissue type, indicating that relative
expression levels vary both with malignancy type and with tissue
type and, moreover, that the difference in expression between
cancer and nonmalignant type varies with tissue type (Table 1).
We conclude that while levels of Ki-67 mRNA can be linked to
cancer, this link varies considerably depending on the tissue
involved. This increase in expression of Ki-67 mRNA in some
tumours is consistent with its established role as a biomarker for
individual proliferating cells, whose contribution to overall tumour
mass would vary between different tissues (Scholzen and Gerdes,
2000; Brown and Gatter, 2002).
In the ANOVAs of hY RNAs, the consistently dominant factor is
malignancy type (Table 1), which ranges from highly significant
(hY4 and hY5) to extremely significant (hY1 and hY3). This
indicates a highly consistent pattern of expression, in which the
relative expression levels of all four hY RNAs are increased in
tumours relative to normal nonmalignant tissue. In addition, hY3
and, to a lesser extent, hY4 RNA, both exhibit significant tissue
type terms, indicating some tendency for expression levels to vary
with tissue type (see also Figure 3). In contrast to the expression of
Ki-67 mRNA, all four hY RNAs reveal either nonsignificant or
borderline significant interaction terms (Table 1), indicating a
simple additive pattern where, for example, higher expression in
cancer and higher expression in tissue X combine to produce very
high expression in cancerous tissue X (Figure 3).
Taken together, these data establish that the expression of hY
RNAs is significantly elevated in human cancers of the bladder,
cervix, colon, kidney, lung and prostate. In particular, the
extremely significant elevation of hY1 and hY3 RNA levels in
these carcinomas (and adenocarcinomas) in all tissue types
investigated identifies them as new cancer biomarkers.
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Figure 3 Tissue-specific overexpression of hY RNAs in human carcinomas and adenocarcinomas. Distributions of relative RNA expression levels and
elevation of tumour-specific relative hY RNA expression are shown for the following tissues: (A) urinary bladder; (B) cervix; (C) colon; (D) kidney; (E) lung;
(F) prostate. Data are presented as detailed for Figure 2.
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sFunctional requirement of hY RNAs for cell proliferation
In the next set of experiments, we investigated whether degrada-
tion of hY RNAs in proliferating human cells leads to an inhibition
of cell proliferation. All four hY RNAs were expressed in several
cell lines investigated (Supplementary Figure S1), in agreement
with earlier reports (Hendrick et al, 1981; Pruijn et al, 1993). Our
previous experiments have already established that RNA inter-
ference (RNAi) against hY1 RNAs is feasible in human cells, and
we reported that degradation of hY1 RNA by two separate siRNAs
results in a reduced proportion of replicating cells (Christov et al,
2006). We have therefore extended this analysis and conducted a
systematic survey of RNAi on all four hY RNAs and analysed the
consequences on cell proliferation (Figure 4) and cell viability
(Figure 5).
For every hY RNA, we synthesised three distinct 21-nucleotide
siRNAs (termed a, b and c) that target specific nucleotide
sequences. Due to the small size of the hY RNAs and their partial
nucleotide sequence conservation, these siRNAs therefore cover
the entire sequences available for specific targeting. siRNAs were
transfected separately into asynchronously proliferating HeLa
cells, and the expression levels of each hY RNA were determined
by quantitative RT–PCR after 48h (Figure 4A). All three siRNAs
specific for hY1 and hY3 RNA resulted in a 2–8 fold reduction in
the amount of the targeted hY RNA (Figure 4A). In contrast, the
relative expression levels of nontargeted 5S rRNA did not change
more than about twofold in these experiments (data not shown).
For hY4 and hY5 RNA we failed to achieve specific degradation
with any of the siRNAs tested (Figure 4A).
Next, we analysed the effects of hY RNA degradation on the
proportion of S phase cells in the transfected populations
(Figure 4B). Transfection of any of the siRNAs directed against
hY1 or hY3 RNA resulted in a two- and threefold reduction of S
phase cells in the population. This reduction is statistically highly
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Figure 3 Continued
Table 1 Analysis of variance of relative RNA expression levels in human tissue samples between different diagnostic groups
P
Type Ki67 mRNA hY1 RNA hY3 RNA hY4 RNA hY5 RNA
Malignancy 0.06 9.7 10
 26 1.7 10
 22 6.3 10
 5 1.9 10
 4
Tissue 2.7 10
 7 0.19 0.002 0.03 0.09
Malignancy tissue interaction 1.9 10
 4 0.32 0.31 0.04 0.20
Relative expression levels for each RNA were obtained as raw DCt values from qRT–PCR analysis of 42 tumour and 24 normal tissue extracts. Individual data were grouped
according to malignancy type (tumour vs normal), tissue type (bladder vs cervix, colon, kidney, lung and prostate) and interaction. ANOVA (two-way between groups) was
performed separately for each RNA. P-values (test¼w
2; model¼Gaussian, glm) are shown for each type and their interaction. Highly significant results (Po0.001) are highlighted
in bold.
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ssignificant (t-test, two-tailed, unpaired, Po0.0001). In contrast,
transfection of siRNA against control nontarget luciferase mRNA,
or of inactive siRNAs directed against hY4 or hY5 RNA, did not
result in a significant reduction in the proportion of S phase cells
(Figure 5B; t-test, two-tailed, unpaired, P40.02). To test for
possible synergistic effects, we cotransfected cells with the two
active siRNAs (against hY1 and hY3 RNA) together. This
cotransfection did not reduce the proportion of S phase cells
more than was achieved using either a single siRNA separately
(Supplementary Figure S2). This observation can most likely be
explained by the redundancy of hY RNAs, which can functionally
substitute for each other in chromosomal DNA replication
(Christov et al, 2006). Finally, we also transfected siRNAs directed
against hY1 RNA into proliferating EJ30 bladder carcinoma,
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Figure 5 Depletion of hY3 RNA is cytostatic and does not cause cell
death. (A) Cell viability assay. RNAi was performed on WI38 lung
fibroblasts and HeLa cervical carcinoma cells. At 0h and 48h post
transfection with the indicated siRNAs, percentages of viable cells were
determined by measuring exclusion of the dye, trypan blue. (B) Cell
morphology. Representative phase contrast micrographs of cells are shown
at 48h after transfection. The mitotic index (%M) for each of these cell
populations was measured by counting 4800 cells per sample and it is
indicated at the bottom left of each field. Scale bar, 10mm.
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Figure 4 RNA interference against hY RNAs. (A) Quantification of
RNA levels after RNAi. Three small interfering RNAs (designated as
siRNAs a, b and c) directed against hY1, hY3, hY4 and hY5 RNA were
transfected into proliferating HeLa cells. RNA was isolated at 48h after
transfection and the amounts of each targeted hY RNA relative to a
calibrator RNA were determined by qRT–PCR. 5.8S rRNA was used as
calibrator for hY1, and HPRT mRNA for the other hY RNAs. The
expression of each target hY RNA after the experimental RNAi is shown as
the percentage of the relative expression levels observed after a control
RNAi against nontarget firefly luciferase mRNA. Mean values are shown for
n independent experiments as indicated. (B) Quantification of replicating S
phase cells after RNAi. At 47h after transfection of asynchronously
proliferating HeLa cells with the indicated siRNAs, replicating cells in the
population were labelled for 1h with BrdU. At 48h, percentages of S phase
cells incorporating BrdU into their chromosomal DNA were determined
by immunofluorescence microscopy. Mean values and s.d. are shown for n
independent experiments.
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lung fibroblast cells. Degradation of hY1 RNA in these cells also
showed a two- and threefold reduction of the proportion of S phase
cells (Supplementary Figure S3). We conclude that the degradation
of hY1 and hY3 RNAs causes significant inhibition of chromo-
somal DNA replication in cultured human cells.
This observation suggests that hY RNA degradation may result
either in a cytostatic or in a cytotoxic inhibition of cell
proliferation. To discriminate between these possibilities, we
determined cell viability and morphology after RNAi (Figure 5).
Mock transfections, or control transfections with a nontarget
siRNA, did not have any effect on cell viability in any cell lines
tested (Figure 5A). Importantly, degradation of hY3 RNA did not
reduce the percentages of viable cells (Figure 5A). Identical results
were obtained when hY1 RNA was degraded instead of hY3 RNA
(data not shown). Furthermore, an assessment of cell morphology
of the transfected cells provided no indication of cell death in any
case (Figure 5B). However, we observed unspecific vacuolarisation
of a subpopulation of transfected cells, irrespective of which siRNA
was used, which can thus be ascribed to the experimental
procedure (Figure 5B). In addition, the mitotic index was reduced
between two- and threefold after degradation of hY3 RNA at 48h
after transfection, compared to the mock- and luciferase siRNA-
transfected cells (Figure 5B). During the siRNA treatment against
hY3 RNA, WI38 and HeLa cells only grew to cell densities of 50
and 59% of the mock-transfected controls, respectively. Taken
together, these data demonstrate that degradation of hY RNAs in
asynchronously proliferating human cells leads to a cytostatic, and
not a cytotoxic, inhibition of cell proliferation.
DISCUSSION
In this study, we have investigated the suitability of noncoding hY
RNAs as new cancer biomarkers and potential targets for anti-
proliferative intervention. We have analysed the relative expres-
sion levels of hY RNAs in human tumours and corresponding
nonmalignant tissues by quantitative RT–PCR. We found that the
relative expression levels of all four hY RNAs are significantly
higher in carcinomas and adenocarcinomas of the urinary bladder,
cervix, colon, kidney, lung and prostate than in corresponding
nonmalignant tissues. Subsequently, we have performed systema-
tic RNA interference against all hY RNAs and analysed the
physiological consequence of their degradation in proliferating
cells. We found that degradation of hY1 and hY3 RNAs in all
human cell lines tested resulted in a significant and cytostatic
inhibition of cell proliferation. Therefore, the correlative expres-
sion data in human tumours and corresponding tissues are
complemented by functional studies, establishing that noncoding
hY RNAs have potential both as new cancer biomarkers and as
targets for anti-proliferative intervention.
The expression of functional wildtype hY RNA genes is very
efficient in human cultured cells, with copy numbers of each
expressed hY RNA reaching the order of 10
5 molecules per cell
(Hendrick et al, 1981; Christov et al, 2006). We determined here
the relative hY RNA expression levels by qRT–PCR, using
preparations of total soluble RNA from tissue samples and from
cultured cells. The apparent relative expression levels of hY5 RNA
in human tissues were several orders of magnitude below those
seen in cultured human cells (Supplementary Figure S1; Christov
et al, 2006). This difference is due in part to the use of differently
primed cDNA libraries for the qRT–PCR amplification. cDNAs
were prepared from tissue RNA by random priming and from RNA
of human cultured cells by specific priming for logistical reasons.
A side-by-side comparison of qRT-PCR amplifications using
specifically and randomly primed cDNA libraries from HeLa cell
extract resulted in about 100-fold reduced levels only of hY5 RNA
in the randomly primed cDNA, but not of the other three hY RNAs
(Supplementary Figure S4). This reduction was significant (t-test,
two-tailed, unpaired, P¼0.008), and may be explained by
inefficient random priming of this shortest and mostly double-
stranded hY RNA for cDNA synthesis. It remains a possibility that
hY5 RNA may also be expressed at lower levels in human tissues
compared to cultured cells.
This qRT–PCR method determines quantitatively the relative RNA
expression levels averaged over all cells present in the entire tissue
sample, or the entire population of cultured cells. Therefore, this
method has the disadvantage of not being able to detect variations of
hY RNA expression levels between individual cells within a given
tissue sample. However, it is both rapid and quantitative, opening up
exciting possibilities for high throughput screening applications and
immediate computational analysis. Furthermore, the sensitivity of
this approach would allow its application to the analysis of small
volume biopsies in clinical situations.
The purified RNA samples from normal and malignant tissues
used in this study were provided from commercial sources with
pathological specifications of tissue type and diagnosis of
malignancy. This information allowed us to find a highly
significant elevation of hY RNA expression levels in tumour
samples (i.e., carcinoma or adenocarcinoma), relative to normal
tissue samples. Consequently, the relative hY RNA expression
levels appear highly promising as sensitive novel cancer biomar-
kers, in particular hY1 and hY3 RNA. Considering the moderate
number of cases (n¼24 normal and n¼42 tumour) and the
selection of six tissues of epithelial lineage investigated, the work
reported here constitutes a pilot study demonstrating the
feasibility of using hY RNAs as novel cancer biomarkers. At
present, we do not have access to patient history data, therefore we
yet cannot evaluate the potential of relative hY RNA expression
levels to be used to form clinical prognoses. A detailed clinical
follow-up study with a large number of cases is now warranted in
which individual case history would be linked to individual hY
RNA levels in malignant and corresponding normal tissue samples.
Noncoding hY RNAs are functionally required for semiconser-
vative DNA replication in vitro using template nuclei from
mammalian late G1 phase cells (Christov et al, 2006; Krude,
2006). Degradation of either hY1 or hY3 RNA (or both) is feasible
in human cells by transfection of specific siRNAs, leading to a
significant reduction of the proportion of replicating cells in the
treated population (S phase index), to a reduction of the mitotic
index and to a cytostatic inhibition of cell proliferation. These data
therefore support a functional requirement of hY RNAs for cell
proliferation, extending the correlation between elevated hY RNA
expression levels and the pathological diagnosis of a given tissue as
cancer-derived. However, we were not able to degrade either hY4
or hY5 RNA by this approach, and thus unable to investigate their
physiological role in vivo. The reason for this failure is unknown,
but it may be linked to the predominantly double-stranded nature
of hY4 and hY5 RNAs, which could interfere with efficient
hybridisation of the siRNAs to its target sequences during RNAi
(Rana, 2007). Likewise, we have been unable to degrade hY5 RNA
in vitro by an antisense oligonucleotide-directed approach
(Christov et al, 2006).
Our observation of a functional role for hY RNAs in mammalian
chromosomal DNA replication and proliferation of human
cultured cells is difficult to reconcile with knockout experiments
in mice. Deletion of the Y RNA-interacting protein Ro60 leads to
reduced levels of homologous mouse Y1 and Y3 RNA expression
levels in adult brain tissue and embryonic stem (ES) cells (Chen
et al, 2003; Xue et al, 2003). Ro60 knockout mice are viable and no
proliferation defects were reported for the mutant ES cells. The
different observations in these two mammalian systems may be
due to different quantitative requirements of human and mouse Y
RNAs for chromosomal DNA replication and cell proliferation, to
physiological differences between model systems (e.g., mouse ES
cells vs human somatic cells) or to different consequences of the
Y RNAs as cancer biomarkers
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(decreased RNA stability upon Ro60 depletion vs nucleolytic
degradation by RNAi). In any case, future experimentation will be
required to resolve these apparently paradoxical observations.
The feasibility of specifically degrading hY1 and hY3 RNA in
intact human cells, thereby causing a cytostatic arrest of cell
proliferation, suggests strongly that these RNAs should be
considered as targets for therapeutic intervention. Future studies
would now be required to assess the feasibility of this approach in
animal models, for instance in mice. We have already shown that
human Y RNAs can substitute for endogenous mouse Y RNAs in
supporting chromosomal DNA replication in isolated mouse cell
nuclei (Christov et al, 2006; Krude, 2006), indicating some degree of
functional conservation of Y RNAs between primates and rodents.
The next step would be to assess feasibility of RNAi-directed,
antisense oligonucleotide-directed, or antagomir-directed degrada-
tion of Y RNAs in accessible tissues and their tumours in mice.
In conclusion, noncoding RNAs are expressed at significantly
higher levels in several human solid tumours of epithelial origin
(carcinomas and adenocarcinomas) compared to corresponding
nonmalignant tissues. This property identifies them as novel
cancer biomarkers with promising diagnostic potential. In
addition, their functional requirement for cell proliferation in
cultured cells identifies them as novel targets for the development
of potential anti-proliferative intervention and cancer treatments.
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